Broker's call: Apollo Hospitals (Buy)

| Updated on September 17, 2020 Published on September 18, 2020

Spark Capital

Apollo Hospitals (Buy)

Target: ₹1,870

CMP: ₹1,777.35

In Q1-FY21, Apollo Hospitals’ Healthcare Services (EBITDA loss of ₹100 crore) and AHLL (EBITDA loss of ₹19 crore) were impacted by lockdown. Pharmacy segment (37 per cent y-o-y EBITDA growth) continued its robust performance.

Healthcare Services’ occupancies should improve (guidance of 50-52 per cent in Q2-FY21 vs 38 per cent in Q1-FY21), led by an increase in non-Covid patient volumes and surgical volumes. In addition to volume recovery, ongoing cost rationalisation initiatives should aid margin improvement (guidance to achieve positive EBITDA in Q2-FY21, targeted cost savings of ₹180-200 crore in FY21 vs. ₹100 crore done in Q1-FY21).

Lower capex guidance and proceeds from SAP restructuring (nearly ₹300 crore, transaction completed in September 2020) should ease leverage position (net debt/EBITDA* of 3.5x as of June 2020).

The management expects net debt to remain stable or decline from current levels (₹3,300 crore in June 2020) at FY21-end.

Our SOTP-based target price of ₹1,870 is based on FY22 EV/EBITDA multiple of 16x for APHS’ Hospitals business; FY22 EV/EBITDA multiple of 18x for back-end pharmacy business; equity valuation of AHEL’s stake in associates and joint ventures.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on September 18, 2020
This article is closed for comments.
Please Email the Editor